Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology

• About 10–15% of all lung cancers are Small Cell Lung Cancer (SCLC), and about 80–85% are NSCLC.
• The three main histological subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the US, approximately 59% of all lung cancers are adenocarcinomas. About 25% of all lung cancers are squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 6% of all lung cancers.
• NSCLC is more common in males as compared to females. In the US, around 56% of males are diagnosed with NSCLC.
• Various types of mutations are commonly observed in NSCLC. There is mounting evidence that substantial molecular and clinical heterogeneity exists within oncogenic driver-defined subgroups of NSCLC. The most frequent biomarkers are EGFR in Japan and KRAS in the US and Europe.
• EGFR exon 19 deletions and Exon 21 L858R substitution (sensitizing mutations) account for approximately 80% of EGFR mutations in NSCLC.
• The most frequent KRAS variant observed in NSCLC is G12C. In the US, KRASG12C is present in ~37% of NSCLC cases.

• In biomarker specific cases, most number of cases is from PD-L1 followed by KRAS, EGFR. On the other hand, NTRK accounted for least number of cases whereas, BRAF and ROS 1 accounted for approximately 5% and 2% cases, respectively.

DelveInsight’s “Non-Small Cell Lung Cancer (NSCLC) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of NSCLC, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

NSCLC Disease Understanding

NSCLC Overview

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. If untreated, SCLC can be fatal in a few weeks, in contrast to most cases of NSCLC. NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. NSCLC can be located in the mid-chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinomas may also be found in patients who have never smoked. Also, itis relatively insensitive to chemotherapy and radiation therapy in comparison with SCLC. NSCLC arises from the epithelial cells of the lung of the central bronchi to terminal alveoli. The histological type of NSCLC correlates with the site of origin, reflecting the variation in respiratory tract epithelium of the bronchi to alveoli. While squamous cell carcinoma starts near a central bronchus usually, Adenocarcinoma and bronchioloalveolar carcinoma typically originate in peripheral lung tissue. Genomic alterations include point mutations such as missense and nonsense mutations, frameshift and slicing site alterations, and rearrangement as well as somatic copy number alterations.

The symptoms of NSCLC and SCLC can be similar, which may include a persistent cough, chest pain, shortness of breath, wheezing, loss of appetite, weight loss, and unusual tiredness. 

NSCLC Diagnosis

Early diagnosis offers the best prognosis for NSCLC. However, NSCLC and other lung cancers can be difficult to diagnose because these cancers often have symptoms mistaken for common illnesses or the effects of long-term smoking. Because of this, 80% of people diagnosed with NSCLC have already progressed to advanced stages, making it more difficult to treat. If lung cancer is suspected, the physician will recommend imaging tests (CT, PET, or MRI scans) to identify abnormalities in and around the lungs. The physician may also examine a sample of mucus under the microscope.

If these initial tests identify cancer, a lung biopsy can be conducted. A bronchoscopy can also be recommended, allowing the physician to visualize and remove tissue. If lung cancer is confirmed, genetic testing can be done on the lung tissue to identify details about the cancer that can help inform treatment.

Further details related to diagnosis will be provided in the report…

NSCLC Epidemiology

The NSCLC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of NSCLC, gender-specific cases of NSCLC, age-specific cases of NSCLC, total incident cases of NSCLC by histology, total cases of NSCLC by stages, total incident cases of NSCLC by genetic mutation/biomarkers, Line wise treated cases of metastatic NSCLC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

• In the US, in 2024, there were approximately 204,800 new cases of NSCLC cancer (~115,500 in men and ~89,300 in women.
• In histology-specific cases, adenocarcinoma accounts for highest number of cases of NSCLC, i.e., approximately 117,030 followed by squamous cell carcinoma in 2024 in the US.
• Among the age-specific contribution, age ≥65 years are affected more by NSCLC than age <65 years. In 2024, there were ~140,000 of NSCLC in age ≥65 years in the US.
• According to the stage-wise classification, the highest number of NSCLC cases in the US in 2024 was reported in Stage I, with ~89,300 cases, followed by Stage II, while the lowest number of cases was reported in Stage IIIb.
• In 2024, the total incident cases of NTRK1/2/3 gene fusion NSCLC in the US was around 450.
• The two main subtypes of KRAS NSCLC are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the Japan, ~4,900 comprised of KRAS G12C, and ~13,300 comprised of KRAS non-G12C in 2024.
• Among EGFR mutations, exon 19 deletions (sensitizing mutations) accounted for the highest number of cases in the US in 2024, with approximately 14,440 cases.
• PD-L1 mutations were categorized into PD-L1 low (expression <50%) and PD-L1 high (expression >50%). In 2024, PD-L1 low accounted for the highest number of cases, with approximately 59,300 cases, compared to PD-L1 high in the US.

NSCLC Report Insights

NSCLC Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

NSCLC Report Key Strengths

• Ten Years Forecast
• 7MM Coverage 
• NSCLC Epidemiology Segmentation

FAQs

• What are the disease risks, burdens, and unmet needs of NSCLC? What will be the growth opportunities across the 7MM concerning the patient population with NSCLC?
• What is the historical and forecasted NSCLC patient pool in the US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.